Molecular Therapeutics: Promise and Challenges

Elise C. Kohn, Yiling Lu, Hongwei Wang, Qinghua Yu, Shuangxing Yu, Hassan Hall, Debra L. Smith, Funda Meric-Bernstam, Gabriel N. Hortobagyi, Gordon Mills

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

The ability to analyze the genetic and epigenetic aberrations present in a particular patient's tumor on a global basis is rapidly maturing. The emerging fields of functional genomics and functional proteomics offer the opportunity to translate these advances into a full comprehension of the pathophysiology of cancer. Linking these approaches to chemical genomics and molecular therapeutics should provide an expanding repertoire of targeted therapeutics for clinical evaluation. Novel clinical trial designs that can determine the efficacy of targeted therapeutics in patients selected for aberrations in the target are needed to evaluate the wealth of new drugs becoming available. The promise of these technologies and advances in our understanding of cancer is immense, making it our responsibility to see them to fruition. These technologies should lead to a new era of individualized molecular medicine, wherein we will treat each patient with a "prescription" based on the genetic changes in each patient's tumor and their own genetic make-up, resulting in more effective and less toxic therapy.

Original languageEnglish (US)
Pages (from-to)39-53
Number of pages15
JournalSeminars in Oncology
Volume31
Issue number1 SUPPL. 3
StatePublished - Feb 1 2004
Externally publishedYes

Fingerprint

Genomics
Neoplasms
Molecular Medicine
Technology
Precision Medicine
Aptitude
Poisons
Therapeutics
Epigenomics
Proteomics
Prescriptions
Clinical Trials
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Kohn, E. C., Lu, Y., Wang, H., Yu, Q., Yu, S., Hall, H., ... Mills, G. (2004). Molecular Therapeutics: Promise and Challenges. Seminars in Oncology, 31(1 SUPPL. 3), 39-53.

Molecular Therapeutics : Promise and Challenges. / Kohn, Elise C.; Lu, Yiling; Wang, Hongwei; Yu, Qinghua; Yu, Shuangxing; Hall, Hassan; Smith, Debra L.; Meric-Bernstam, Funda; Hortobagyi, Gabriel N.; Mills, Gordon.

In: Seminars in Oncology, Vol. 31, No. 1 SUPPL. 3, 01.02.2004, p. 39-53.

Research output: Contribution to journalReview article

Kohn, EC, Lu, Y, Wang, H, Yu, Q, Yu, S, Hall, H, Smith, DL, Meric-Bernstam, F, Hortobagyi, GN & Mills, G 2004, 'Molecular Therapeutics: Promise and Challenges', Seminars in Oncology, vol. 31, no. 1 SUPPL. 3, pp. 39-53.
Kohn EC, Lu Y, Wang H, Yu Q, Yu S, Hall H et al. Molecular Therapeutics: Promise and Challenges. Seminars in Oncology. 2004 Feb 1;31(1 SUPPL. 3):39-53.
Kohn, Elise C. ; Lu, Yiling ; Wang, Hongwei ; Yu, Qinghua ; Yu, Shuangxing ; Hall, Hassan ; Smith, Debra L. ; Meric-Bernstam, Funda ; Hortobagyi, Gabriel N. ; Mills, Gordon. / Molecular Therapeutics : Promise and Challenges. In: Seminars in Oncology. 2004 ; Vol. 31, No. 1 SUPPL. 3. pp. 39-53.
@article{c25c4167401e4f2b9829bccbd6c4b3e1,
title = "Molecular Therapeutics: Promise and Challenges",
abstract = "The ability to analyze the genetic and epigenetic aberrations present in a particular patient's tumor on a global basis is rapidly maturing. The emerging fields of functional genomics and functional proteomics offer the opportunity to translate these advances into a full comprehension of the pathophysiology of cancer. Linking these approaches to chemical genomics and molecular therapeutics should provide an expanding repertoire of targeted therapeutics for clinical evaluation. Novel clinical trial designs that can determine the efficacy of targeted therapeutics in patients selected for aberrations in the target are needed to evaluate the wealth of new drugs becoming available. The promise of these technologies and advances in our understanding of cancer is immense, making it our responsibility to see them to fruition. These technologies should lead to a new era of individualized molecular medicine, wherein we will treat each patient with a {"}prescription{"} based on the genetic changes in each patient's tumor and their own genetic make-up, resulting in more effective and less toxic therapy.",
author = "Kohn, {Elise C.} and Yiling Lu and Hongwei Wang and Qinghua Yu and Shuangxing Yu and Hassan Hall and Smith, {Debra L.} and Funda Meric-Bernstam and Hortobagyi, {Gabriel N.} and Gordon Mills",
year = "2004",
month = "2",
day = "1",
language = "English (US)",
volume = "31",
pages = "39--53",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 3",

}

TY - JOUR

T1 - Molecular Therapeutics

T2 - Promise and Challenges

AU - Kohn, Elise C.

AU - Lu, Yiling

AU - Wang, Hongwei

AU - Yu, Qinghua

AU - Yu, Shuangxing

AU - Hall, Hassan

AU - Smith, Debra L.

AU - Meric-Bernstam, Funda

AU - Hortobagyi, Gabriel N.

AU - Mills, Gordon

PY - 2004/2/1

Y1 - 2004/2/1

N2 - The ability to analyze the genetic and epigenetic aberrations present in a particular patient's tumor on a global basis is rapidly maturing. The emerging fields of functional genomics and functional proteomics offer the opportunity to translate these advances into a full comprehension of the pathophysiology of cancer. Linking these approaches to chemical genomics and molecular therapeutics should provide an expanding repertoire of targeted therapeutics for clinical evaluation. Novel clinical trial designs that can determine the efficacy of targeted therapeutics in patients selected for aberrations in the target are needed to evaluate the wealth of new drugs becoming available. The promise of these technologies and advances in our understanding of cancer is immense, making it our responsibility to see them to fruition. These technologies should lead to a new era of individualized molecular medicine, wherein we will treat each patient with a "prescription" based on the genetic changes in each patient's tumor and their own genetic make-up, resulting in more effective and less toxic therapy.

AB - The ability to analyze the genetic and epigenetic aberrations present in a particular patient's tumor on a global basis is rapidly maturing. The emerging fields of functional genomics and functional proteomics offer the opportunity to translate these advances into a full comprehension of the pathophysiology of cancer. Linking these approaches to chemical genomics and molecular therapeutics should provide an expanding repertoire of targeted therapeutics for clinical evaluation. Novel clinical trial designs that can determine the efficacy of targeted therapeutics in patients selected for aberrations in the target are needed to evaluate the wealth of new drugs becoming available. The promise of these technologies and advances in our understanding of cancer is immense, making it our responsibility to see them to fruition. These technologies should lead to a new era of individualized molecular medicine, wherein we will treat each patient with a "prescription" based on the genetic changes in each patient's tumor and their own genetic make-up, resulting in more effective and less toxic therapy.

UR - http://www.scopus.com/inward/record.url?scp=11144354140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144354140&partnerID=8YFLogxK

M3 - Review article

C2 - 15052542

AN - SCOPUS:11144354140

VL - 31

SP - 39

EP - 53

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 3

ER -